299 related articles for article (PubMed ID: 22081481)
1. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Pan CY; Yang W; Tou C; Gause-Nilsson I; Zhao J
Diabetes Metab Res Rev; 2012 Mar; 28(3):268-75. PubMed ID: 22081481
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
Yang W; Pan CY; Tou C; Zhao J; Gause-Nilsson I
Diabetes Res Clin Pract; 2011 Nov; 94(2):217-24. PubMed ID: 21871686
[TBL] [Abstract][Full Text] [Related]
3. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
Rosenstock J; Aguilar-Salinas C; Klein E; Nepal S; List J; Chen R;
Curr Med Res Opin; 2009 Oct; 25(10):2401-11. PubMed ID: 19650754
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
6. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Rosenstock J; Sankoh S; List JF
Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
[TBL] [Abstract][Full Text] [Related]
7. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Hollander P; Li J; Allen E; Chen R;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4810-9. PubMed ID: 19864452
[TBL] [Abstract][Full Text] [Related]
8. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
[TBL] [Abstract][Full Text] [Related]
9. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Hollander PL; Li J; Frederich R; Allen E; Chen R;
Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
Kania DS; Gonzalvo JD; Weber ZA
Clin Ther; 2011 Aug; 33(8):1005-22. PubMed ID: 21802144
[TBL] [Abstract][Full Text] [Related]
14. Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Sjöstrand M; Iqbal N; Lu J; Hirshberg B
Diabetes Res Clin Pract; 2014 Aug; 105(2):185-91. PubMed ID: 24947443
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
[TBL] [Abstract][Full Text] [Related]
17. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
[TBL] [Abstract][Full Text] [Related]
18. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
Bonora E; Bryzinski B; Hirshberg B; Cook W
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Nowicki M; Rychlik I; Haller H; Warren M; Suchower L; Gause-Nilsson I; Schützer KM
Int J Clin Pract; 2011 Dec; 65(12):1230-9. PubMed ID: 21977965
[TBL] [Abstract][Full Text] [Related]
20. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
